ArticleEuropean journal of nuclear medicine and molecular imaging2024
A bis-boron boramino acid PET tracer for brain tumor diagnosis.
Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 12 citations in OpenAlex.
- Detailed pharmacokinetic features of a novel bis-boronEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Boron-10 carriers and their applications in boron neutron capture therapy.Precision radiation oncology · 2026Review
- Spatial Targeting of Sialic Acid Receptors for MRI/BNCT-Integrated Boron Drug-Based Antitumor Therapy.Pharmaceutical research · 2026Article
- ADMET-Guided Design and In Silico Planning of Boron Delivery Systems for BNCT: From Transport and Biodistribution to PBPK-Informed Irradiation Windows.Molecules (Basel, Switzerland) · 2026Review
- Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model.Nature communications · 2026Article
- CD98 Light Chain LAT1 Tracers in PET-CT Diagnosis of Cancer Patients.Anti-cancer agents in medicinal chemistry · 2026Review
- LAT1-specific PET radiotracers: Development and clinical experiences of a new class of cancer-specific radiopharmaceuticals.Theranostics · 2025Review
- LAT1 expression in head and neck cancer: a prognostic biomarker with potential relevance for BNCT.Frontiers in oncology · 2025Article
- A histogram of [EJNMMI research · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 2 institutions in 3 countries.
Funding
Abstract
purposeBoramino acids are a class of amino acid biomimics that replace the carboxylate group with trifluoroborate and can achieve the
methodsThis study reports a trifluoroborate-derived boronophenylalanine (BBPA), a derived boronophenylalanine (BPA) for BNCT, as a promising PET tracer for tumor imaging.
resultsCompetition inhibition assays in cancer cells suggested the cell accumulation of [
conclusionThis study outlines a clinical trial with [
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.